Kathryn Lumb

Representative Experience

• Represented Dicerna Pharmaceuticals (Nasdaq: DRNA) in a global collaboration agreement with Novo Nordisk A/S (NYSE: NVO) to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases. Under the terms of the agreement, Dicerna will receive an upfront payment of $175 million, a $50 million equity investment and up to $357.5 million per target in development, regulatory, and commercialization milestone payments.
• Represented Bridge Biotherapeutics in a collaboration and license agreement in excess of €1.1 billion in upfront and milestone payments, plus royalties, with Boehringer Ingelheim to develop Bridge Biotherapeutics’ autotaxin inhibitor BBT-877 for idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung diseases. 
• Represented LegoChem Bio in a $400+ million multi-target research collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE: TAK).
• Advised Applied Genetic Technologies Corporation (Nasdaq: AGTC) in a strategic collaboration with Otonomy, Inc. (Nasdaq: OTIC) to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy.

Professional Experience

• Northeast Intellectual Property, Co-founder
• Elan Pharmaceuticals, Chief Intellectual Property Officer
• Pfizer Inc., Senior Patent Attorney, Patent Counsel, Assistant General Counsel